References
- Bermudez L. E., Kolonoski P., Young L. S., Inderlied C. B. Activity of KRM-1648 alone or in combination with ethambutol or clarithromycin against Mycobacterium avium in beige mouse model of disseminated infection. Antimicrobial Agents and Chemotherapy 1994; 38: 1844–1848
- Emori M., Saito H., Sato K., Tomioka H., Setogawa T., Hidaka T. Therapeutic efficacy of benzoxazinorifamycin KRM-1648 against experimental Mycobacterium avium infection induced in rabbits. Agents Antimicrobial and Chemotherapy 1993; 37: 722–728
- Fujii K., Tsuji A., Miyazaki S., Yamaguchi K., Goto S. In vitro and in vivo antibacterial activities of KRM-1648 and KRM-1657, new rifamycin derivatives. Antimicrobial Agents and Chemotherapy 1994; 38: 1118–1122
- Inderlied C. B., Young L. S., Yamada J. K. Determination of in vitro susceptibility of Mycobacterium avium complex isolates to antimicrobial agents by various methods. Antimicrobial Agents and Chemotherapy 1987; 31: 1697–1702
- Inderlied C. B., Barbara-Burnham L., Wu M., Young L. S., Bermudez L. E. Activity of the benzoxazinorifamycin KRM-1648 and ethambutol against Mycobacterium avium complex in vitro and macrophages. Antimicrobial Agents and Chemotherapy 1994; 38: 1838–1343
- Klemens S. P., Grossi M. A., Cynamon M. H. Activity of KRM-1648, a new benzoxazinorifamycin, against Mycobacterium tuberculosis in a murine model. Antimicrobial Agents and Chemotherapy 1994; 38: 2245–2248
- Kuze F., Yamamoto T., Amitani R., Suzuki K. In vitro activities of new rifamycin derivatives against mycobacteria. Kekkaku 1991; 66: 7–12
- Luna-Herrera J., Reddy M. V., Gangadharam P. R. J. In vitro activity of the benzoxazinorifamycin KRM-1648 against drug-susceptible and multidrug-resistant tubercle bacilli. Antimicrobial Agents and Chemotherapy 1995; 39: 440–444
- Saito H., Tomioka H., Sato K., Emori M., Yamane T., Yamashita K., Hosoe K., Hidaka T. In vitro antimycobacterial activities of newly synthesized benzoxazinofifamycin. Antimicrobial Agents and Chemotherapy 1991; 35: 542–547
- Tilton R. C. Antimicrobial susceptibility tests. Antimicrobial Therapy, A. J. Ristuccia, B. A. Cunha. Raven, New York 1984; 137–145
- Tomioka H., Saito H., Sato K., Yamane T., Yamashita K., Hosoe K., Fujii K., Hidaka T. Chemotherapeutic efficacy of a newly synthesized benzoxazinorifamycin, KRM-1648, against Mycobacterium avium complex infection induced in mice. Antimicrobial Agents and Chemotherapy 1992; 36: 387–393
- Tomioka H., Saito H., Fujii K., Sato K., Hidaka T. In vitro antimicrobial activity benzoxazinorifamycin, KRM-1648, against Mycobacterium avium complex determined by the radiometric method. Antimicrobial Agents and Chemotherapy 1993; 37: 67–70
- Yamamoto T., Amitani R., Kuze F., Suzuki K. In vitro activities of new rifamycin derivatives against Mycobacterium tuberculosis and M. avium complex. Kekkaku 1990; 65: 805–810
- Yamane T., Hashizume T., Yamashita K., Konishi E., Hosoe K., Hidaka T., Watanabe K., Kawaharada H., Yamamoto T., Kuze F. Synthesis and biological activity of 3′-hydroxy-5′-aminobenzoxazinorifamycin derivatives. Chemical and Pharmaceutical Bulletin 1993; 41: 148–155